Gilead Sciences (GILD) 102.57 $GILD
5 Drugs That Are the Face of Prescription Drug Reform
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 15, 8:41AM CST
Image source: Flickr user StockMonkeys.com. Think fast: what's the first thing that comes to mind when I say "prescription drugs?" Were you too busy reaching for your wallet to think of anything? Don't worry, you're probably not alone. ...
MNK: 56.94 (+3.53), VRX: 75.41 (+1.64), VRTX: 123.05 (+5.75), GILD: 102.57 (-1.66)
Gilead Presents New Data at The Liver Meeting 2015
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced it will present results from multiple studies of Viread(R) (tenofovir disoproxil fumarate, TDF) 300 mg for the treatment of chronic hepatitis B virus (HBV) infection, as well as new data regarding its investigational agents for HBV and nonviral liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), at The Liver Meeting 2015 taking place November 13-17 in San Francisco.
GILD: 102.57 (-1.66)
Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (NASDAQ:GILD) today announced it will present 32 scientific presentations related to its approved medicines and investigational therapies for the treatment of chronic hepatitis C virus (HCV) infection at The Liver Meeting 2015 in San Francisco. Data include results from studies of Harvoni(R) (ledipasvir/sofosbuvir) and Sovaldi(R) (sofosbuvir) that advance the understanding of the profiles of these drugs in several patient populations. Detailed results from the four Phase 3 ASTRAL studies evaluating the company's next potential single tablet regimen - a once-daily combination of velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, with sofosbuvir (SOF) - also will be presented.
GILD: 102.57 (-1.66)
Regeneron Tests Buy Point As New Drug Shows Promise
at Investor's Business Daily - Fri Nov 13, 5:24PM CST
After bouncing back from the biotech sell-off that followed Hillary Clinton's accusations of Big Pharma price gouging, Regeneron Pharmaceuticals (REGN) now faces a new test: resistance at its latest buy point. The maker of Eylea eye injections has...
GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 52.72 (-1.20), SWKS: 74.83 (-1.01), GILD: 102.57 (-1.66), SUNE: 4.93 (+0.39), FB: 103.95 (-4.07), MRK: 53.03 (unch), STZ: 132.20 (-1.18), ILMN: 165.65 (+10.26), AAPL: 112.34 (-3.38)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BXLT: 33.79 (+0.54)
Tyco Q4 Earnings In Line with Estimates, Revenues Lag
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:28AM CST
Tyco (TYC) reported fourth-quarter fiscal 2015 adjusted income from continuing operations of 61 cents, in line with the Zacks Consensus Estimate.
TYC: 35.31 (-1.19), GILD: 102.57 (-1.66), LAKE: 12.95 (+0.29), ALRM: 16.13 (-0.41)
Gilead Sciences (GILD) Breaks Through Support at $103.23
Comtex SmarTrend(R) - Fri Nov 13, 9:08AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $105.16 and have already reached the first level of support at $103.23. Investors may be interested in a cross of the next downside pivot targets of $102.22 and $99.28.
GILD: 102.57 (-1.66)
5 Stocks Generating Incredible Return on Assets
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 8:56AM CST
Is EPS really a true measure of profits? Let us show you a much better gauge of a company's profitability: the Return on Assets ratio.
NVO: 52.93 (-0.57), BIDU: 193.95 (-4.19), CBOE: 69.56 (+0.04), PFIE: 1.27 (+0.07), GILD: 102.57 (-1.66), WMT: 56.42 (-0.53)
5 Toxic Stocks to Sell Now
at The Street - Fri Nov 13, 8:45AM CST
Here's a technical look at five stocks that you need to unload from your portfolio.
AMX: 15.95 (-0.39), MDLZ: 43.27 (-0.37), GILD: 102.57 (-1.66), SUNE: 4.93 (+0.39), CHL: 57.48 (-1.67)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BMY: 64.15 (+0.43)
Gilead, Regeneron Stocks Weather Drug Pricing Furor
at Investor's Business Daily - Thu Nov 12, 5:30PM CST
Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry's drug-pricing practices and fears of...
MNK: 56.94 (+3.53), ESRX: 82.99 (-1.47), VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), HZNP: 17.99 (+0.38), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
U.S. FDA Approves New Indications for Harvoni(R), Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Business Wire - Thu Nov 12, 4:54PM CST
--- Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for Treatment-Experienced Genotype 1 Patients with Cirrhosis -
GILD: 102.57 (-1.66)
Watch for Gilead Sciences to Potentially Rebound After Falling 2.76% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 4:45PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $104.16 to a high of $107.10. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $107.03 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 102.57 (-1.66)
Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 2.76% Sell Off
Comtex SmarTrend(R) - Thu Nov 12, 4:44PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $104.16 to a high of $107.10. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $107.03 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 102.57 (-1.66)
Regeneron Recovers From Clinton Biotech Beat Down
at Investor's Business Daily - Thu Nov 12, 10:27AM CST
Biotech stocks and drugmakers like Valeant Pharmaceuticals (VRX) took a beating in September when Hillary Clinton accused Big Pharma of price gouging. But Regeneron Pharmaceuticals (REGN) has now bounced back into a buy zone. The New York-based...
VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
ENZ: 4.50 (+0.14), GILD: 102.57 (-1.66), RTRX: 18.72 (+0.42), EXEL: 5.40 (-0.01)
A Trio of Catalysts Lift Merck Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 11, 8:07AM CST
Shares of global pharmaceutical giant Merck shot higher by 11% in October, based on data from S&P Capital IQ , thanks to three big catalysts. The first came early in the month, with the Food and Drug Administration granting Merck its...
GILD: 102.57 (-1.66), MRK: 53.03 (unch)
5 Drugs That Are the Face of Prescription Drug Reform
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 15, 8:41AM CST
Image source: Flickr user StockMonkeys.com. Think fast: what's the first thing that comes to mind when I say "prescription drugs?" Were you too busy reaching for your wallet to think of anything? Don't worry, you're probably not alone. ...
MNK: 56.94 (+3.53), VRX: 75.41 (+1.64), VRTX: 123.05 (+5.75), GILD: 102.57 (-1.66)
Gilead Presents New Data at The Liver Meeting 2015
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced it will present results from multiple studies of Viread(R) (tenofovir disoproxil fumarate, TDF) 300 mg for the treatment of chronic hepatitis B virus (HBV) infection, as well as new data regarding its investigational agents for HBV and nonviral liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), at The Liver Meeting 2015 taking place November 13-17 in San Francisco.
GILD: 102.57 (-1.66)
Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (NASDAQ:GILD) today announced it will present 32 scientific presentations related to its approved medicines and investigational therapies for the treatment of chronic hepatitis C virus (HCV) infection at The Liver Meeting 2015 in San Francisco. Data include results from studies of Harvoni(R) (ledipasvir/sofosbuvir) and Sovaldi(R) (sofosbuvir) that advance the understanding of the profiles of these drugs in several patient populations. Detailed results from the four Phase 3 ASTRAL studies evaluating the company's next potential single tablet regimen - a once-daily combination of velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, with sofosbuvir (SOF) - also will be presented.
GILD: 102.57 (-1.66)
Regeneron Tests Buy Point As New Drug Shows Promise
at Investor's Business Daily - Fri Nov 13, 5:24PM CST
After bouncing back from the biotech sell-off that followed Hillary Clinton's accusations of Big Pharma price gouging, Regeneron Pharmaceuticals (REGN) now faces a new test: resistance at its latest buy point. The maker of Eylea eye injections has...
GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 52.72 (-1.20), SWKS: 74.83 (-1.01), GILD: 102.57 (-1.66), SUNE: 4.93 (+0.39), FB: 103.95 (-4.07), MRK: 53.03 (unch), STZ: 132.20 (-1.18), ILMN: 165.65 (+10.26), AAPL: 112.34 (-3.38)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BXLT: 33.79 (+0.54)
Tyco Q4 Earnings In Line with Estimates, Revenues Lag
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:28AM CST
Tyco (TYC) reported fourth-quarter fiscal 2015 adjusted income from continuing operations of 61 cents, in line with the Zacks Consensus Estimate.
TYC: 35.31 (-1.19), GILD: 102.57 (-1.66), LAKE: 12.95 (+0.29), ALRM: 16.13 (-0.41)
Gilead Sciences (GILD) Breaks Through Support at $103.23
Comtex SmarTrend(R) - Fri Nov 13, 9:08AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $105.16 and have already reached the first level of support at $103.23. Investors may be interested in a cross of the next downside pivot targets of $102.22 and $99.28.
GILD: 102.57 (-1.66)
5 Stocks Generating Incredible Return on Assets
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 8:56AM CST
Is EPS really a true measure of profits? Let us show you a much better gauge of a company's profitability: the Return on Assets ratio.
NVO: 52.93 (-0.57), BIDU: 193.95 (-4.19), CBOE: 69.56 (+0.04), PFIE: 1.27 (+0.07), GILD: 102.57 (-1.66), WMT: 56.42 (-0.53)
5 Toxic Stocks to Sell Now
at The Street - Fri Nov 13, 8:45AM CST
Here's a technical look at five stocks that you need to unload from your portfolio.
AMX: 15.95 (-0.39), MDLZ: 43.27 (-0.37), GILD: 102.57 (-1.66), SUNE: 4.93 (+0.39), CHL: 57.48 (-1.67)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BMY: 64.15 (+0.43)
Gilead, Regeneron Stocks Weather Drug Pricing Furor
at Investor's Business Daily - Thu Nov 12, 5:30PM CST
Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry's drug-pricing practices and fears of...
MNK: 56.94 (+3.53), ESRX: 82.99 (-1.47), VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), HZNP: 17.99 (+0.38), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
U.S. FDA Approves New Indications for Harvoni(R), Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Business Wire - Thu Nov 12, 4:54PM CST
--- Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for Treatment-Experienced Genotype 1 Patients with Cirrhosis -
GILD: 102.57 (-1.66)
Watch for Gilead Sciences to Potentially Rebound After Falling 2.76% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 4:45PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $104.16 to a high of $107.10. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $107.03 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 102.57 (-1.66)
Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 2.76% Sell Off
Comtex SmarTrend(R) - Thu Nov 12, 4:44PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $104.16 to a high of $107.10. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $107.03 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 102.57 (-1.66)
Regeneron Recovers From Clinton Biotech Beat Down
at Investor's Business Daily - Thu Nov 12, 10:27AM CST
Biotech stocks and drugmakers like Valeant Pharmaceuticals (VRX) took a beating in September when Hillary Clinton accused Big Pharma of price gouging. But Regeneron Pharmaceuticals (REGN) has now bounced back into a buy zone. The New York-based...
VRX: 75.41 (+1.64), GILD: 102.57 (-1.66), AMGN: 151.55 (+0.57), SNY: 42.99 (-0.65), REGN: 548.90 (-3.63)
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
ENZ: 4.50 (+0.14), GILD: 102.57 (-1.66), RTRX: 18.72 (+0.42), EXEL: 5.40 (-0.01)
A Trio of Catalysts Lift Merck Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 11, 8:07AM CST
Shares of global pharmaceutical giant Merck shot higher by 11% in October, based on data from S&P Capital IQ , thanks to three big catalysts. The first came early in the month, with the Food and Drug Administration granting Merck its...
GILD: 102.57 (-1.66), MRK: 53.03 (unch)
